HRP20151397T1 - DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE - Google Patents
DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE Download PDFInfo
- Publication number
- HRP20151397T1 HRP20151397T1 HRP20151397TT HRP20151397T HRP20151397T1 HR P20151397 T1 HRP20151397 T1 HR P20151397T1 HR P20151397T T HRP20151397T T HR P20151397TT HR P20151397 T HRP20151397 T HR P20151397T HR P20151397 T1 HRP20151397 T1 HR P20151397T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- acetyl
- coa carboxylase
- disease
- Prior art date
Links
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims 1
- 108010018763 Biotin carboxylase Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Photographic Processing Devices Using Wet Methods (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (5)
1. Spoj, naznačen time što je spoj Formule (I)
[image]
,
ili njegova farmaceutski prihvatljiva sol.
2. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljivu pomoćnu tvar, razrjeđivač ili podlogu.
3. Spoj u skladu s patentnim zahtjevom 1 ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u postupku liječenja bolesti, stanja ili poremećaja koje se modulira inhibiranjem jednog ili više enzima acetil-CoA karboksilaza.
4. Spoj u skladu s patentnim zahtjevom 1 ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u postupku u skladu s patentnim zahtjevom 3, gdje je bolest, stanje ili poremećaj dijabetes tip 2, poremećaji povezani s dijabetesom, nealkoholna bolest masne jetre (NAFLD) ili jetrena otpornost na inzulin.
5. Spoj u skladu s patentnim zahtjevom 1 ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u postupku u skladu s patentnim zahtjevom 3, gdje je bolest, stanje ili poremećaj dijabetes tip 2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161478240P | 2011-04-22 | 2011-04-22 | |
| EP12718387.9A EP2699576B1 (en) | 2011-04-22 | 2012-04-09 | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors |
| PCT/IB2012/051732 WO2012143813A1 (en) | 2011-04-22 | 2012-04-09 | Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151397T1 true HRP20151397T1 (hr) | 2016-01-15 |
Family
ID=46025823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151397TT HRP20151397T1 (hr) | 2011-04-22 | 2015-12-21 | DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE |
Country Status (41)
| Country | Link |
|---|---|
| US (4) | US8802688B2 (hr) |
| EP (1) | EP2699576B1 (hr) |
| JP (1) | JP5657174B2 (hr) |
| KR (1) | KR101567659B1 (hr) |
| CN (2) | CN103492388A (hr) |
| AP (1) | AP3499A (hr) |
| AR (1) | AR086198A1 (hr) |
| AU (1) | AU2012245996B2 (hr) |
| CA (1) | CA2831380C (hr) |
| CL (1) | CL2013002794A1 (hr) |
| CO (1) | CO6801757A2 (hr) |
| CR (1) | CR20130464A (hr) |
| CU (1) | CU24164B1 (hr) |
| CY (1) | CY1117122T1 (hr) |
| DK (1) | DK2699576T3 (hr) |
| DO (1) | DOP2013000243A (hr) |
| EA (1) | EA022375B1 (hr) |
| EC (1) | ECSP13013038A (hr) |
| ES (1) | ES2561452T3 (hr) |
| GE (1) | GEP20166474B (hr) |
| GT (1) | GT201300258A (hr) |
| HR (1) | HRP20151397T1 (hr) |
| HU (1) | HUE028602T2 (hr) |
| IL (1) | IL228949A (hr) |
| MA (1) | MA35061B1 (hr) |
| ME (1) | ME02312B (hr) |
| MX (1) | MX348860B (hr) |
| MY (1) | MY162167A (hr) |
| NI (1) | NI201300111A (hr) |
| NZ (1) | NZ616156A (hr) |
| PE (1) | PE20141187A1 (hr) |
| PL (1) | PL2699576T3 (hr) |
| PT (1) | PT2699576E (hr) |
| RS (1) | RS54526B1 (hr) |
| SG (1) | SG194142A1 (hr) |
| SI (1) | SI2699576T1 (hr) |
| TN (1) | TN2013000393A1 (hr) |
| TW (1) | TWI464171B (hr) |
| UA (1) | UA107753C2 (hr) |
| UY (1) | UY34027A (hr) |
| WO (1) | WO2012143813A1 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP3283A (en) * | 2009-11-10 | 2015-05-31 | Pfizer | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| CN102491974B (zh) * | 2011-12-12 | 2013-08-07 | 南京药石药物研发有限公司 | 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法 |
| CA2903431C (en) | 2013-03-14 | 2022-12-06 | Kalyra Pharmaceuticals, Inc. | Bicyclopentane analgesic compounds |
| EP2994139B1 (en) | 2013-05-10 | 2019-04-10 | Gilead Apollo, LLC | Acc inhibitors and uses thereof |
| WO2014182951A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
| JP6417401B2 (ja) | 2013-05-10 | 2018-11-07 | ギリアド アポロ， エルエルシー | Ａｃｃ阻害剤及びその使用 |
| CN105530940A (zh) * | 2013-09-12 | 2016-04-27 | 辉瑞大药厂 | 乙酰辅酶a羧化酶抑制剂用于治疗寻常痤疮的用途 |
| EP3670496A3 (en) | 2013-10-17 | 2020-09-30 | Shionogi&Co., Ltd. | Acc2 inhibitors |
| CN105814013A (zh) * | 2013-12-12 | 2016-07-27 | 卡利拉制药公司 | 双环烷基化合物及合成 |
| US10654812B2 (en) | 2014-03-07 | 2020-05-19 | Recurium Ip Holdings Llc | Propellane derivates and synthesis |
| US10457502B2 (en) | 2014-05-22 | 2019-10-29 | Symbotic Canada Ulc | Tool and method for layer depalletizing |
| US10308609B2 (en) | 2014-09-17 | 2019-06-04 | Zeno Royalties & Milestones, LLC | Bicyclic compounds |
| US11058703B2 (en) * | 2015-12-31 | 2021-07-13 | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease |
| CN106580986B (zh) * | 2016-11-28 | 2017-09-15 | 王保亮 | 一种治疗少弱精子症的药物组合物 |
| WO2018213140A1 (en) | 2017-05-15 | 2018-11-22 | Zeno Royalties & Milestones, LLC | Analgesic compounds |
| CA3082867C (en) * | 2017-11-21 | 2022-05-10 | Pfizer Inc. | Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid |
| CN111574530B (zh) * | 2020-04-21 | 2022-07-26 | 徐州医科大学 | 一种acc抑制剂及其医药用途 |
| WO2024140923A1 (zh) * | 2022-12-30 | 2024-07-04 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0901786B1 (en) | 1997-08-11 | 2007-06-13 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
| EP1383501B1 (en) | 2001-02-28 | 2007-04-04 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| EP1478437B1 (en) | 2002-02-27 | 2005-08-31 | Pfizer Products Inc. | Acc inhibitors |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| JPWO2004092179A1 (ja) | 2003-04-14 | 2006-07-06 | 日本曹達株式会社 | スピロ誘導体、製造法および抗酸化薬 |
| JP2005119987A (ja) | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| GEP20084421B (en) | 2004-05-12 | 2008-07-10 | Pfizer Prod Inc | Proline derivatives and their use as dipeptidyl peptidase iv inhibitors |
| WO2005113069A2 (en) | 2004-05-14 | 2005-12-01 | Research Development Foundation | Use of circumin and analogues as inhibitors of acc2 |
| JP4069159B2 (ja) | 2004-05-25 | 2008-04-02 | ファイザー・プロダクツ・インク | テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| US7410976B2 (en) | 2005-07-19 | 2008-08-12 | Merck & Co., Inc. | Spirochromanone derivatives |
| CA2617042A1 (en) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
| US8071770B2 (en) | 2005-11-18 | 2011-12-06 | Merck Sharp & Dohme Corp. | Spirohydantoin aryl CGRP receptor antagonists |
| CA2641766A1 (en) | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| SI2463283T1 (sl) | 2006-04-20 | 2014-09-30 | Pfizer Products Inc. | Kondezirane fenil amino heterociklične spojine za preprečevanje in zdravljenje bolezni, ki jih posreduje glukokinaza |
| JP2010511035A (ja) | 2006-11-29 | 2010-04-08 | ファイザー・プロダクツ・インク | スピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| JPWO2008102749A1 (ja) * | 2007-02-20 | 2010-05-27 | 武田薬品工業株式会社 | 複素環化合物 |
| JP5404601B2 (ja) | 2007-04-12 | 2014-02-05 | ファイザー・インク | 新規な３−アミド−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルバルデヒド誘導体 |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| ES2545231T3 (es) | 2008-05-28 | 2015-09-09 | Pfizer Inc. | Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa |
| EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| CA2729412A1 (en) * | 2008-07-04 | 2010-01-07 | Banyu Pharmaceutical Co., Ltd. | Novel spirochromanone carboxylic acids |
| EP2310015A4 (en) | 2008-07-14 | 2011-10-26 | Cropsolution Inc | ACETYL-COENZYME-CARBOXYLASE MODULATORS AND METHODS OF USE THEREOF |
| CA2729581A1 (en) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Fluorinated heteroaryls |
| EA018492B1 (ru) | 2008-08-28 | 2013-08-30 | Пфайзер Инк. | Диоксабицикло[3.2.1]октан-2,3,4-триольные производные |
| WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
| CA2754685A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides |
| EP2406253B1 (en) | 2009-03-11 | 2013-07-03 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
| CA2754523A1 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| JP2012526097A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Ｇｐｒ１１９調節因子 |
| EP2427448A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
| AU2010255422B2 (en) | 2009-06-05 | 2014-04-10 | Pfizer Inc. | 1- ( piperidin-4-yl) -pyrazole derivatives as GPR 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| EP2499140A1 (en) * | 2009-11-10 | 2012-09-19 | Pfizer Inc. | N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| AP3283A (en) | 2009-11-10 | 2015-05-31 | Pfizer | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| CA2811033C (en) * | 2010-09-30 | 2015-10-20 | Pfizer Inc. | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
-
2012
- 2012-04-09 ME MEP-2015-214A patent/ME02312B/me unknown
- 2012-04-09 GE GEAP201213267A patent/GEP20166474B/en unknown
- 2012-04-09 MY MYPI2013003372A patent/MY162167A/en unknown
- 2012-04-09 DK DK12718387.9T patent/DK2699576T3/en active
- 2012-04-09 CA CA2831380A patent/CA2831380C/en active Active
- 2012-04-09 PE PE2013002387A patent/PE20141187A1/es not_active Application Discontinuation
- 2012-04-09 WO PCT/IB2012/051732 patent/WO2012143813A1/en active Application Filing
- 2012-04-09 CN CN201280019621.3A patent/CN103492388A/zh active Pending
- 2012-04-09 CN CN201610487378.8A patent/CN106117205B/zh not_active Expired - Fee Related
- 2012-04-09 SG SG2013075148A patent/SG194142A1/en unknown
- 2012-04-09 MA MA36357A patent/MA35061B1/fr unknown
- 2012-04-09 AP AP2013007129A patent/AP3499A/xx active
- 2012-04-09 AU AU2012245996A patent/AU2012245996B2/en not_active Ceased
- 2012-04-09 CU CU20130126A patent/CU24164B1/es active IP Right Grant
- 2012-04-09 NZ NZ616156A patent/NZ616156A/en not_active IP Right Cessation
- 2012-04-09 HU HUE12718387A patent/HUE028602T2/hu unknown
- 2012-04-09 EA EA201391288A patent/EA022375B1/ru not_active IP Right Cessation
- 2012-04-09 RS RS20160026A patent/RS54526B1/en unknown
- 2012-04-09 ES ES12718387.9T patent/ES2561452T3/es active Active
- 2012-04-09 SI SI201230417T patent/SI2699576T1/sl unknown
- 2012-04-09 EP EP12718387.9A patent/EP2699576B1/en active Active
- 2012-04-09 JP JP2014505745A patent/JP5657174B2/ja active Active
- 2012-04-09 PL PL12718387T patent/PL2699576T3/pl unknown
- 2012-04-09 PT PT127183879T patent/PT2699576E/pt unknown
- 2012-04-09 KR KR1020137030875A patent/KR101567659B1/ko active IP Right Grant
- 2012-04-09 MX MX2013012313A patent/MX348860B/es active IP Right Grant
- 2012-04-18 TW TW101113766A patent/TWI464171B/zh not_active IP Right Cessation
- 2012-04-19 UY UY0001034027A patent/UY34027A/es not_active Application Discontinuation
- 2012-04-20 AR ARP120101364A patent/AR086198A1/es unknown
- 2012-04-21 US US13/452,839 patent/US8802688B2/en active Active
- 2012-09-04 UA UAA201311822A patent/UA107753C2/ru unknown
-
2013
- 2013-09-12 CR CR20130464A patent/CR20130464A/es unknown
- 2013-09-27 CL CL2013002794A patent/CL2013002794A1/es unknown
- 2013-09-27 TN TNP2013000393A patent/TN2013000393A1/fr unknown
- 2013-10-17 IL IL228949A patent/IL228949A/en active IP Right Grant
- 2013-10-18 GT GT201300258A patent/GT201300258A/es unknown
- 2013-10-18 NI NI201300111A patent/NI201300111A/es unknown
- 2013-10-21 DO DO2013000243A patent/DOP2013000243A/es unknown
- 2013-10-24 CO CO13252716A patent/CO6801757A2/es active IP Right Grant
- 2013-11-22 EC ECSP13013038 patent/ECSP13013038A/es unknown
-
2014
- 2014-07-08 US US14/325,420 patent/US20140323730A1/en not_active Abandoned
-
2015
- 2015-01-09 US US14/593,370 patent/US20150112068A1/en not_active Abandoned
- 2015-08-07 US US14/820,884 patent/US20150336958A1/en not_active Abandoned
- 2015-12-21 HR HRP20151397TT patent/HRP20151397T1/hr unknown
-
2016
- 2016-01-14 CY CY20161100038T patent/CY1117122T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151397T1 (hr) | DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE | |
| HRP20171512T1 (hr) | Derivati betulina | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| BR112014003225A2 (pt) | profármacos de treprostinil ligados a veículo | |
| CA2918938C (en) | Substituted aminopyrimidine compounds and methods of use | |
| SI2935307T1 (en) | Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures | |
| NZ609527A (en) | N1/n2-lactam acetyl-coa carboxylase inhibitors | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| ECSP13012668A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
| WO2012162254A8 (en) | Inhibitors of lrrk2 kinase activity | |
| BR112015000106A2 (pt) | moduladores heterocíclicos de síntes de lipídio | |
| MX2016000307A (es) | Farmaco para el tratamiento de la esteatosis hepatica no alcoholica. | |
| HRP20221304T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| WO2012094598A3 (en) | Pharmaceutical compositions of iron for oral administration | |
| HRP20160203T1 (hr) | Pripravci koji sadrže 15-hepe i postupci njihove upotrebe | |
| GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| WO2011012816A3 (fr) | Formulation pharmaceutique | |
| HRP20171824T1 (hr) | (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A | |
| EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
| BR112013022213A2 (pt) | administração parenteral de tapentadol | |
| WO2012048129A3 (en) | Inhibitors of polo-like kinase | |
| MX2021010046A (es) | Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas. | |
| EA201391026A1 (ru) | Кристаллическое производное оксазина и его применение в качестве ингибитора bace | |
| EA201270653A1 (ru) | Антагонист dpи его применение |